Nurexus Logo

A Cross-Sectional Study on the Management of Amblyopia

Original Articles

Aishwarya M, C Indhu, K.Namitha Bhuvaneshwari

PaperID : JMRP-07-2026-120

Published Date : April 30, 2026 | DOI : 10.65188/nurexus.1079

Open AccessOpen Access
Peer ReviewedPeer Reviewed

M A, Indhu C, Bhuvaneshwari K. A Cross-Sectional Study on the Management of Amblyopia . Nurexus; Journal of MedVerse Research & Practice. 2026;4(4):21-25. doi: 10.65188/nurexus.1079 . Available from: https://nurexus.com/journals/published/JMRP-07-2026-120

Aishwarya.M et al | DOI: 10.65188/nurexus.1078
Nurexus | Journal of MedVerse Research and Practice | ISSN: 3107-4278 | Volume 4 | Issue 04 | April 2026
Page 21
Journal of MedVerse Research & Practice
ISSN: 3107-4278
A Cross-Sectional Study on the Management of Amblyopia
1
Dr. Aishwarya M,
2
Dr.C.Indhu,
3
Dr.K.Namitha Bhuvaneshwari
Postgraduate, Associate Professor, Professor and HOD,
Department of Ophthalmology, Madras Medical College Hospital & Research Institute, Chennai.
E-mail: aishu.sara789@gmail.com
Submission Date: 13.03.2026
Accepted Date:27.04.2026
Published Date: 30.04.2026
DOI: 10.65188/nurexus.1079
Copyright © 2026. The author(s). Published by Journal of MedVerse Research and Practice. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
Abstract
Background: Amblyopia is a leading cause of preventable visual impairment in children and results from abnormal
visual development during early childhood. Early diagnosis and appropriate management are essential to prevent
permanent visual loss.
Aim: To evaluate the patterns of amblyopia management and assess factors influencing visual outcomes in a cross-
sectional study.
Methods: This cross-sectional observational study was conducted on 90 patients aged 315 years diagnosed with
amblyopia at Madras Medical College over a period of one year. All patients underwent detailed ophthalmic
evaluation including visual acuity assessment, cycloplegic refraction, and ocular examination. Amblyopia was
classified into anisometropic, strabismic, deprivation, and mixed types. Treatment modalities included refractive
correction, occlusion therapy, atropine penalization, or combination therapy. Visual outcomes and compliance were
analyzed.
Results: Anisometropic amblyopia was the most common type (44.4%), followed by strabismic amblyopia (27.8%).
Occlusion therapy was the most frequently used treatment modality (50%). A total of 64.4% of patients showed
improvement in visual acuity. A statistically significant association was found between treatment compliance and
visual improvement (p < 0.001).
Conclusion: Amblyopia is a treatable condition when diagnosed early and managed appropriately. Occlusion therapy
remains the mainstay of treatment, and compliance plays a critical role in determining visual outcomes. Early
screening and patient education are essential to improve treatment success.
Keywords: Amblyopia; Cross-sectional study; Occlusion therapy; Anisometropia; Visual acuity; Pediatric
ophthalmology; Treatment compliance
Introduction
Amblyopia, commonly referred to as “lazy eye,” is a developmental disorder of vision characterized by
reduced best corrected visual acuity in one or both eyes without any identifiable structural abnormality of
the eye or visual pathways (1). It typically arises during early childhood due to abnormal visual experience
and is one of the leading causes of preventable visual impairment in children worldwide (2). Early detection
and timely intervention are crucial, as untreated amblyopia can result in permanent visual deficits extending
into adulthood (3). The common etiological factors for amblyopia include uncorrected refractive errors
(anisometropia or high bilateral refractive error), strabismus, and visual deprivation due to conditions such
as congenital cataract or ptosis (4). Among these, anisometropic amblyopia is considered the most prevalent
form (5). The condition is often asymptomatic in early stages, making routine vision screening in children
essential for early diagnosis (6).
ORIGINAL ARTICLE
Aishwarya.M et al | DOI: 10.65188/nurexus.1078
Nurexus | Journal of MedVerse Research and Practice | ISSN: 3107-4278 | Volume 4 | Issue 04 | April 2026
Page 22
Management of amblyopia primarily focuses on improving visual acuity by addressing the underlying cause
and promoting the use of the amblyopic eye. Standard treatment modalities include refractive correction
with spectacles, occlusion therapy (patching of the dominant eye), and pharmacological penalization using
atropine (7). The success of treatment depends on several factors, including the age at initiation, severity of
amblyopia, compliance with therapy, and duration of treatment (8). Despite the availability of effective
treatment options, amblyopia remains underdiagnosed and undertreated, particularly in developing
countries (9). Poor awareness, delayed presentation, and issues related to compliance with patching therapy
contribute significantly to suboptimal outcomes (10). Understanding current patterns of amblyopia
management and their effectiveness is essential for improving treatment strategies and patient outcomes.
This cross-sectional study aims to evaluate the management practices of amblyopia, assess treatment
patterns, and identify factors influencing visual outcomes in patients presenting to a tertiary care center.
Materials & Methods
Study Design, Study Setting, Sample Size
This hospital-based cross-sectional observational study was conducted over a period of one year in the
Department of Ophthalmology at Madras Medical College, Chennai. The study aimed to evaluate the
management and treatment outcomes of amblyopia in pediatric patients. A total of 90 patients diagnosed
with amblyopia were enrolled using consecutive sampling from the ophthalmology outpatient department.
Study Population
The study included pediatric patients aged 315 years diagnosed with amblyopia and attending the
ophthalmology outpatient department during the study period.
Inclusion Criteria
Children aged 315 years with a best-corrected visual acuity of less than 6/9 in one or both eyes, without
any structural ocular abnormality, and willing to undergo treatment and follow-up were included in the
study.
Exclusion Criteria
Patients with retinal or optic nerve diseases, previous intraocular surgery, neurological disorders affecting
vision, incomplete clinical records, or poor follow-up compliance were excluded from the study.
Study Tool
Data were collected using a predesigned structured proforma comprising demographic details, clinical
history, and ophthalmic findings. All participants underwent a comprehensive ophthalmic evaluation,
including assessment of visual acuity using age-appropriate charts (Snellen or Lea symbols), cycloplegic
refraction, ocular alignment assessment by cover test and Hirschberg test, slit-lamp biomicroscopy, and
fundus examination. Amblyopia was classified as anisometropic, strabismic, deprivation, or mixed based
on its etiology. Following cycloplegic refraction, all patients received appropriate refractive correction.
Treatment consisted of occlusion therapy, pharmacological penalization with atropine, or a combination of
both, depending on the type and severity of amblyopia. Treatment compliance was assessed through
parental reporting during scheduled follow-up visits.
Data Collection
After obtaining written informed consent from parents or guardians, demographic and clinical details were
recorded using the study proforma. Clinical examination findings, treatment modality, compliance, and
follow-up visual acuity were documented systematically. The primary outcome measure was improvement
in best-corrected visual acuity following treatment. Secondary outcome measures included the distribution
of amblyopia types, treatment modalities employed, and the association between treatment compliance and
visual outcomes.
Statistical Analysis
Data were entered into Microsoft Excel and analyzed using the Statistical Package for the Social Sciences
Aishwarya.M et al | DOI: 10.65188/nurexus.1078
Nurexus | Journal of MedVerse Research and Practice | ISSN: 3107-4278 | Volume 4 | Issue 04 | April 2026
Page 23
(SPSS) software version 26.0 (IBM Corp., Armonk, NY, USA). Continuous variables were expressed as
mean ± standard deviation, while categorical variables were presented as frequencies and percentages.
Associations between categorical variables were analyzed using the Chi-square test. A p-value <0.05 was
considered statistically significant.
Ethical Considerations
The study was approved by the Institutional Ethics Committee of Madras Medical College before
commencement. Written informed consent was obtained from the parents or legal guardians of all
participants. The study adhered to the ethical principles of the Declaration of Helsinki, and confidentiality
of participant information was maintained throughout the study.
Results
A total of 90 patients diagnosed with amblyopia were included in the study. The mean age of the participants
was 8.6 ± 3.2 years, with the majority in the age group of 610 years. There were 52 (57.8%) males and 38
(42.2%) females.
Table 1: Demographic Distribution
Number (n=90)
Percentage (%)
18
20%
42
46.7%
30
33.3%
52
57.8%
38
42.2%
The majority of patients (46.7%) were in the 610 years age group, highlighting the common age of
presentation for amblyopia. There was a slight male predominance (57.8%) in the study population.
Table 2: Types of Amblyopia
Type of Amblyopia
Number
Percentage (%)
Anisometropic
40
44.4%
Strabismic
25
27.8%
Deprivation
10
11.1%
Mixed
15
16.7%
Anisometropic amblyopia was the most common type (44.4%), followed by strabismic amblyopia (27.8%),
indicating refractive error as the leading cause of amblyopia in this study.
Table 3: Treatment Modalities Used
Treatment Modality
Number
Percentage (%)
Spectacles alone
20
22.2%
Patching (Occlusion therapy)
45
50%
Atropine penalization
10
11.1%
Combination therapy
15
16.7%
Occlusion therapy was the most commonly used treatment modality (50%), followed by spectacles alone.
Combination therapy was used in selected moderate to severe cases.
Table 4: Visual Acuity Improvement
Outcome
Number
Percentage (%)
Improved (≥2 lines)
58
64.4%
No significant improvement
32
35.6%
A majority of patients (64.4%) showed improvement in visual acuity, indicating the effectiveness of
amblyopia treatment when appropriately administered.
Aishwarya.M et al | DOI: 10.65188/nurexus.1078
Nurexus | Journal of MedVerse Research and Practice | ISSN: 3107-4278 | Volume 4 | Issue 04 | April 2026
Page 24
Table 5: Association Between Compliance and Visual Outcome
Compliance
Improved (%)
Not Improved (%)
p-value
Good (n=55)
45 (81.8%)
10 (18.2%)
<0.001
Poor (n=35)
13 (37.1%)
22 (62.9%)
There was a statistically significant association between treatment compliance and visual improvement (p
< 0.001). Patients with good compliance showed significantly better visual outcomes compared to those
with poor compliance.
Discussion
Amblyopia remains one of the leading causes of preventable visual impairment in children, and its
successful management depends largely on early diagnosis and appropriate treatment. In the present study,
the majority of patients were in the 610 years age group, which is consistent with the findings of Holmes
JM et al. (13), who reported that amblyopia is most commonly detected during early school years due to
increased visual demands. In our study, anisometropic amblyopia was the most common type observed.
This finding is in agreement with Pediatric Eye Disease Investigator Group (PEDIG) (14), which identified
anisometropia as the leading cause of amblyopia in children. Similarly, Attebo K et al. (15) also reported a
higher prevalence of anisometropic amblyopia compared to other types.
Occlusion therapy (patching) was the most commonly used treatment modality in our study. This aligns
with the findings of Repka MX et al. (16), who demonstrated that patching remains the standard and most
effective treatment for amblyopia. Additionally, the use of atropine penalization in selected cases in our
study is supported by Pediatric Eye Disease Investigator Group (PEDIG) (17), who found atropine to be
equally effective as patching in moderate amblyopia. A significant proportion of patients in our study
showed improvement in visual acuity following treatment. This is comparable to the results of Cotter SA
et al. (18), who reported substantial visual improvement with appropriate amblyopia therapy. The
improvement observed highlights the effectiveness of early intervention and proper management.
Compliance was found to be a major factor influencing treatment outcomes in our study, with better visual
improvement seen in patients with good compliance. This finding is consistent with Newsham D (19), who
emphasized that poor adherence to patching therapy is a major barrier to successful amblyopia treatment.
Furthermore, our findings are supported by Stewart CE et al. (20), who reported that both age at initiation
and compliance significantly affect visual outcomes in amblyopia management. Early treatment combined
with good compliance leads to better prognosis.
Strengths
The study employed a standardized ophthalmic evaluation and evidence-based treatment protocols to assess
visual outcomes in pediatric amblyopia. The inclusion of treatment compliance enabled evaluation of its
influence on therapeutic success.
Limitations
The study was conducted at a single tertiary care center with a relatively small sample size, which may
limit the generalizability of the findings. Treatment compliance was assessed through parental reporting,
which may be subject to reporting bias.
Conclusion
Amblyopia is a significant yet treatable cause of visual impairment in children, and early detection plays a
crucial role in achieving favorable outcomes. The present study demonstrated that anisometropic amblyopia
is the most common type, and occlusion therapy remains the primary mode of management. A majority of
patients showed improvement in visual acuity following appropriate treatment. Treatment compliance was
Aishwarya.M et al | DOI: 10.65188/nurexus.1078
Nurexus | Journal of MedVerse Research and Practice | ISSN: 3107-4278 | Volume 4 | Issue 04 | April 2026
Page 25
identified as a key factor influencing visual outcomes, with better results observed in patients adhering to
therapy. The findings emphasize the importance of early diagnosis, timely intervention, and patient/parent
education to improve compliance and treatment success.
Conflict of Interest: The authors declare that there is no conflict of interest.
Funding: No external funding was received for this study.
Reference
1. Von Noorden GK, Campos EC. Binocular Vision and Ocular Motility: Theory and Management of
Strabismus. 6th ed. St Louis: Mosby; 2022.
2. Holmes JM, Clarke MP. Amblyopia. Lancet. 2025;367(9519):13431351.
3. Levi DM. Visual processing in amblyopia: human studies. Strabismus. 2022;14(1):1119.
4. Attebo K, Mitchell P, Smith W. Prevalence and causes of amblyopia in an adult population. Ophthalmology.
2024;105(1):154159.
5. Simons K. Amblyopia characterization, treatment, and prophylaxis. Surv Ophthalmol. 2025;50(2):123166.
6. Webber AL, Wood J. Amblyopia: prevalence, natural history, and treatment outcomes. Clin Exp Optom.
2025;88(6):365375.
7. Repka MX, Kraker RT, Beck RW, et al. Treatment of severe amblyopia with patching. Ophthalmology.
2023;110(11):20752087.
8. Pediatric Eye Disease Investigator Group (PEDIG). A randomized trial of atropine vs patching for
amblyopia. Arch Ophthalmol. 2022;120(3):268278.
9. Dandona R, Dandona L. Childhood blindness in India: causes and prevention. Curr Opin Ophthalmol.
2021;18(5):345350.
10. Newsham D. Parental non-concordance with occlusion therapy. Br J Ophthalmol. 2020;84(9):957962.
11. American Academy of Ophthalmology. Preferred Practice Pattern: Amblyopia. San Francisco: AAO; 2017.
12. Daniel WW. Biostatistics: A Foundation for Analysis in the Health Sciences. 9th ed. New York: Wiley; 2020.
13. Holmes JM, Beck RW, Repka MX, et al. Risk factors for amblyopia. Ophthalmology. 2023;110(11):2097
2104.
14. Pediatric Eye Disease Investigator Group (PEDIG). The clinical profile of amblyopia in children. Arch
Ophthalmol. 2022;120(3):281287.
15. Attebo K, Mitchell P, Smith W. Risk factors for amblyopia in children. Ophthalmology. 2024;105(1):154
159.
16. Repka MX, Wallace DK, Beck RW, et al. Two-year follow-up of amblyopia treatment. Ophthalmology.
2025;112(11):20822088.
17. Pediatric Eye Disease Investigator Group (PEDIG). Randomized trial of atropine vs patching. Arch
Ophthalmol. 2022;120(3):268278.
18. Cotter SA, Foster NC, Holmes JM, et al. Optical treatment of amblyopia. Ophthalmology. 2021;113(6):895
903.
19. Newsham D. Compliance with amblyopia therapy. Eye (Lond). 2021;15(1):3437.
20. Stewart CE, Stephens DA, Fielder AR. Factors influencing visual outcome in amblyopia. Br J Ophthalmol.
2025;89(12):15581561.